Corbus Pharmaceuticals Holdings Inc. (CRBP) Now Covered by Analysts at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) in a research note published on Tuesday morning. The brokerage issued a buy rating and a $17.00 price objective on the biopharmaceutical company’s stock.
Separately, Aegis set a $12.00 target price on Corbus Pharmaceuticals Holdings and gave the company a buy rating in a research note on Monday, September 19th.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 9.79 on Tuesday. The firm’s market capitalization is $428.29 million. The stock’s 50 day moving average price is $5.88 and its 200 day moving average price is $3.48. Corbus Pharmaceuticals Holdings has a 52-week low of $1.01 and a 52-week high of $9.95.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative net margin of 890.44% and a negative return on equity of 107.10%. Analysts expect that Corbus Pharmaceuticals Holdings will post ($0.40) earnings per share for the current year.
In other Corbus Pharmaceuticals Holdings news, CFO Sean F. Moran acquired 30,800 shares of Corbus Pharmaceuticals Holdings stock in a transaction dated Thursday, September 8th. The stock was acquired at an average cost of $5.12 per share, for a total transaction of $157,696.00. Following the completion of the transaction, the chief financial officer now owns 330,110 shares in the company, valued at approximately $1,690,163.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Barbara White acquired 38,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction dated Wednesday, August 17th. The shares were acquired at an average price of $3.15 per share, with a total value of $119,700.00. Following the completion of the transaction, the insider now owns 161,067 shares of the company’s stock, valued at approximately $507,361.05. The disclosure for this purchase can be found here. 11.60% of the stock is owned by company insiders.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.